ERYTECH Pharma announces the oral presentation of positive Phase II clinical trial results in Acute Lymphoblastic Leukemia. Post author:admERY Post published:June 17, 2012 Post category:Newsroom You Might Also Like ERYTECH Reports Top-line Results of Phase 2b Study of Eryaspase for the Treatment of AML December 8, 2017 Erytech announces trading suspension of its ordinary shares on Euronext Paris November 10, 2017 ERYTECH to Present at Jefferies Virtual Healthcare Conference November 12, 2020
ERYTECH Reports Top-line Results of Phase 2b Study of Eryaspase for the Treatment of AML December 8, 2017
